149968-10-5

Basic information

• Product Name: 1-{3-(1E)-2-(7-Chloro(2-Quinolyl))Vinylphenyl}Prop-2-En-1-Ol
• Synonyms: BenzeneMethanol,3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]-a-ethenyl-;1-{3-(1E)-2-(7-Chloro(2-Quinolyl))Vinylphenyl}Prop-2-En-1-Ol;(E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)prop-2-en-1-ol;1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]prop-2-en-1-ol
• CAS NO: 149968-10-5
• Molecular Formula: C₂₀H₁₆ClNO
• Molecular Weight: 321.80014
• Mol File: 149968-10-5.mol

Chemical Properties

• Boiling Point: 504.125°C at 760 mmHg (Cal.) ref.
• Flash Point: 258.686°C (Cal.) ref.
• Appearance: /
• Density: 1.264g/cm3 (Cal.) ref.
• Storage Temp.: 2-8°C
• PKA: 13.47±0.20(Predicted)
• CAS DataBase Reference: 1-{3-(1E)-2-(7-Chloro(2-Quinolyl))Vinylphenyl}Prop-2-En-1-Ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-{3-(1E)-2-(7-Chloro(2-Quinolyl))Vinylphenyl}Prop-2-En-1-Ol(149968-10-5)
• EPA Substance Registry System: 1-{3-(1E)-2-(7-Chloro(2-Quinolyl))Vinylphenyl}Prop-2-En-1-Ol(149968-10-5)

Safety Data

• Hazardous Substances Data: 149968-10-5(Hazardous Substances Data)

Usage

Uses

(E)-1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-2-propen-1-ol is a useful synthetic intermediate in the synthesis of L-699392, a LTD4 antagonist.

Upstream product

• 1826-67-1 vinyl magnesium bromide 
• 120578-03-2 (E)-3-[2-(7-chloro-2-quinolinyl)ethenyl]benzaldehyde 
• 7732-18-5 water 
• 3536-96-7 vinylmagnesium chloride 
• 4965-33-7 2-methyl-7-chloroquinoline 
• 626-19-7 Isophthalaldehyde 

Downstream Products

• 203940-08-3 1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}propenone 
• 142521-91-3 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-((4-hydroxy-4-methylpentyl)thio)propyl)phenyl)-2-methylpropanoic acid 
• 151767-02-1 Montelukast sodium 
• 577953-88-9 1-(((1(R)-(3-(2-(7-chloro-2-quinolinil)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid dicyclohexylamine salt 
• 1359172-54-5 (S)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxy-ethyl)-phenyl]-propan-1-ol 
• 1359172-33-0 C₃₃H₃₈ClNO₄SSi 
• 1359172-36-3 (1-{(R)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)vinyl]phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxyethyl)phenyl]propylsulfanylmethyl}cyclopropyl)acetic acid methyl ester 
• 1359172-44-3 1-{3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxyethyl)phenyl]propan-1-one 
• 1258428-71-5 trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 174813-83-3 methyl (E)-2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-oxopropyl)benzoate 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 150026-72-5 -2-<3-<3-<2-(7-chloro-2-quinolinyl)ethenyl>phenyl>-3-hydroxypropyl>benzoic acid methyl ester 

Relevant articles and documents

PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS

The present invention relates to an improved process for the preparation of a compound having formula (I). The compound having formula (I) is the backbone diol precursor/intermediate used to produce montelukast sodium. Montelukast sodium is a leukotriene

Continuous recycling of homogeneous Pd/Cu catalysts for cross-coupling reactions

Given the importance of homogeneous catalysts recycling in organic chemistry, we have developed a unique microfluidic loop system for automated continuous recirculation of a soluble polymer supported metal catalyst for novel isocyanide cross-coupling reactions under thermomorphic multicomponent solvent (TMS) conditions. Our system provides an innovative approach for the chemical library synthesis of quinazolinone derivatives as well as an important intermediate of Merck's LTD4 antagonist "Singulair" with efficient continuous homogeneous catalyst recycling.

AN IMPROVED PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM AND ITS INTERMEDIATES

The present invention relates to a process for the preparation of montelukast sodium (formula 1) and formula 4. The invention concerns the coupling of thiol derivative, Methyl 1 - (mercaptomethyl)cyclopropane acetate with mesylate of formula 4 compound using alkyl substituted ammonium hydroxide base, alkali amides and purification of Montelukast acid by crystallization in suitable organic solvents. The invention further concerns to provide an improved process of montelukast intermediates having good yield and quality

Process for the preparation of optically active ethenylphenyl-alcohols

Optically active ethenylphenyl-alcohols of formula or its mirror image, wherein R1 is unsubstituted or substituted heteroaryl and R2 is phenyl or substituted aryl, are prepared by asymmetric hydrogenation of the corresponding ketones applying hydrogen gas in the presence of specific platinum metal complex catalysts.

PREPARATION OF MONTELUKAST AND ITS SALTS

There is provided a process for the preparation of montelukast of the Formula (I).

A PROCESS FOR SYNTHESIZING DIOL (VIII)-AN INTERMEDIATE OF MONTELUKAST SODIUM

A process comprises preparing benzaldehyde of formula I in a conventional manner, reacting the said benzaldehyde I with Grignard reagent in water miscible etheral solvent to precipitate the alcohol of formula (II) by addition of ammonium salt and water followed by isolating the alcohol thus precipitated by any known methods and then oxidizing directly under "Swern's conditions" to get a ketone of formula m, enolizing the said ketone in presence of a mild base such as alkali metal alkoxide and then reacting it with dialkyl carbonate under conditions effective to yield a β- ketoester of formula IV, benzylating the said β-ketoester so obtained in the preceding step to form the benzoate of formula V in presence of mild inorganic base followed by decarboxylating the said benzoate to a mixture of a ketoester of formula VI and its corresponding acid of formula VIA in the presence of acidic conditions, alkylating the acid VIA present in the mixture in the preceding step to obtain ketoester of formula VI and purifying it if so desired, asymmetrically reducing the ketoester of formula VI, to a chiral alcohol of formula VII using (-) diisopinocamphenylchloroborane (-DIPC1) in presence of less than 4 times v/w aprotic solvent and optionally in presence of Lewis base with respect to the said ketoester of formula VI, treating the said chiral alcohol VII with cerium halo salt, and alkylmagnesium halide followed by isolating the title compound using hyflow supercel and ammonium chloride to get the intermediate diol of formula VIII. Atemately, the said alcohol to Heck coupling with methyl-2-iodobenzoate in presence of Lewis base, acetonitrile, and palladium acetate to yield ketoester (VI), which is converted to diol (VIII) as described herein above.

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

QUINOLINE-CONTAINING KETOACIDS AS LEUKOTRIENE ANTAGONISTS

Compounds having the formula I: STR1 are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection.

Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Compounds having the formula I: STR1 are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.